Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
By strengthening the company's fibrotic disease development pipeline, Bridge will enhance its strategic focus on the development of comprehensive treatment solutions for idiopathic pulmonary fibrosis (IPF)
Tc99m tilmanocept is designed for the precise identification of lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
The drug will be manufactured at the group's injectables manufacturing facility at Jarod, Gujarat
The HD-550 endoscopy system has been available outside of the USA since 2019
Marks the second of three biosimilars Amneal expects to receive U.S. approval for in 2022
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
This product will be manufactured at Lupin’s Nagpur facility in India
Subscribe To Our Newsletter & Stay Updated
